ACADIA Pharmaceuticals Inc. (ACAD) Financial Statements (2024 and earlier)

Company Profile

Business Address 12830 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments438,865416,823520,706631,958697,429473,520
Cash and cash equivalents188,657114,846147,435326,028189,680134,758
Short-term investments250,208301,977373,271305,930507,749338,762
Receivables102,35063,08065,34450,28237,87427,789
Inventory, net of allowances, customer advances and progress billings40,44711,56014,0989,6826,3414,070
Inventory40,44711,56014,0989,6826,3414,070
Prepaid expense39,09121,39823,89225,69418,60620,727
Other undisclosed current assets(4,628)(4,924)(6,217)   
Total current assets:616,125507,937617,823717,616760,250526,106
Noncurrent Assets
Operating lease, right-of-use asset51,85555,57358,26847,2839,524
Property, plant and equipment4,6126,0218,0479,1613,1803,309
Intangible assets, net (including goodwill)65,490  1,1082,5854,062
Intangible assets, net (excluding goodwill)65,490  1,1082,5854,062
Restricted cash and investments5,7705,7705,7705,7704,7874,826
Other noncurrent assets4767,5873,9971,6782,8571,899
Other undisclosed noncurrent assets4,6284,9246,217   
Total noncurrent assets:132,83179,87582,29965,00022,93314,096
TOTAL ASSETS:748,956587,812700,122782,616783,183540,202
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities254,254125,63096,068105,96774,82659,565
Accounts payable17,54312,7466,8768,4937,2223,167
Accrued liabilities236,711112,88489,19297,47467,60456,398
Total current liabilities:254,254125,63096,068105,96774,82659,565
Noncurrent Liabilities
Long-term debt and lease obligation:   56,12644,4606,361 
Liabilities, other than long-term debt62,94761,7697,0345,1802,861 
Other liabilities15,1479,0747,0345,1802,861 
Operating lease, liability47,80052,69556,12644,4606,361
Other undisclosed noncurrent liabilities      1,558
Total noncurrent liabilities:62,94761,76963,16049,6409,2221,558
Total liabilities:317,201187,399159,228155,60784,04861,123
Equity
Equity, attributable to parent431,755400,413540,894627,009699,135479,079
Common stock161616161514
Additional paid in capital2,862,5522,770,9232,694,6462,612,6632,402,9451,948,300
Accumulated other comprehensive income (loss)24(975)(192)36297(372)
Accumulated deficit(2,430,837)(2,369,551)(2,153,576)(1,985,706)(1,704,122)(1,468,863)
Total equity:431,755400,413540,894627,009699,135479,079
TOTAL LIABILITIES AND EQUITY:748,956587,812700,122782,616783,183540,202

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues726,437517,235484,145441,755339,076223,807
Cost of revenue(41,638)(10,166)(19,141)(20,550)(19,598)(18,330)
Cost of goods and services sold(41,638)(10,166)(10,843)(10,211)(11,344)(2,700)
Other undisclosed gross profit  (1)8,29810,3398,2545,953
Gross profit:684,799507,068473,302431,544327,732211,430
Operating expenses(758,178)(730,665)(635,443)(707,791)(566,023)(452,921)
Other undisclosed operating income (loss)  1(8,298)(10,339)(8,254)(5,953)
Operating loss:(73,379)(223,596)(170,439)(286,586)(246,545)(247,444)
Nonoperating income (expense)5,1093,542(2,329)(1,994)1,994(3,680)
Investment income, nonoperating    (997)997(1,840)
Other nonoperating income (expense)5,1093,542(2,329)(997)997(1,840)
Other undisclosed income from continuing operations before equity method investments, income taxes    7,60710,1687,188
Loss from continuing operations before equity method investments, income taxes:(68,270)(220,054)(172,768)(280,973)(234,383)(243,936)
Other undisclosed income from continuing operations before income taxes17,2346,6105,249   
Income (loss) from continuing operations before income taxes:(51,036)(213,444)(167,519)(280,973)(234,383)(243,936)
Income tax expense(10,250)(2,531)(351)(611)(876)(1,256)
Loss from continuing operations:(61,286)(215,975)(167,870)(281,584)(235,259)(245,192)
Loss before gain (loss) on sale of properties:(167,870)(281,584)(235,259)(245,192)
Net loss available to common stockholders, diluted:(61,286)(215,975)(167,870)(281,584)(235,259)(245,192)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(61,286)(215,975)(167,870)(281,584)(235,259)(245,192)
Other comprehensive income (loss) 999(783)(228)(261)66927
Other undisclosed comprehensive income      
Comprehensive loss:(60,287)(216,758)(168,098)(281,845)(234,590)(245,165)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(60,287)(216,758)(168,098)(281,845)(234,590)(245,165)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: